GlassScriptPhysician profile
Neil J Goldberg
NPI 1780722181
$202,652.57
in general payments reported to CMS, 2019-2025
31 companies · $1,683 in 2025
The $1,683 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75K · 2020: $25K · 2021: $52K · 2022: $38K · 2023: $8,743 · 2024: $1,355 · 2025: $1,683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,974 · Food and Beverage: $3,743 · Travel and Lodging: $835 · Education: $229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,974.00 |
| Food and Beverage | $3,743.45 |
| Travel and Lodging | $834.91 |
| Education | $228.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $107,147.93 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $78,859.90 | 2019-2023 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $7,664.72 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $2,592.23 | 2019 | |
| Medtronic, INC. | $1,360.51 | 2023-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Lilly USA, LLC | $730.72 | 2019-2024 | Mounjaro, Trulicity, Jardiance |
| Insulet Corporation | $630.92 | 2019-2025 | Omnipod |
| Mannkind Corporation | $414.00 | 2019-2024 | Afrezza |
| Corcept Therapeutics | $387.30 | 2021-2024 | Korlym |
| Ibsa Pharma INC. | $366.55 | 2019-2023 | Tirosint, Licart |
| Abbott Laboratories | $362.90 | 2019-2024 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $292.35 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $256.71 | 2019-2025 | Jardiance, Ofev |
| Medtronic Minimed, INC. | $223.21 | 2019-2020 | |
| Zealand Pharma US, INC. | $188.52 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $174.64 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $158.48 | 2023-2024 | |
| Cvrx, INC. | $148.60 | 2022 | |
| Vistapharm, INC. | $135.22 | 2021 | |
| Ascendis Pharma Endocrinology INC | $135.18 | 2025 | |
| Janssen Scientific Affairs, LLC | $122.57 | 2019 | |
| Abbvie INC. | $54.51 | 2019-2022 | |
| Lexicon Pharmaceuticals, INC. | $47.05 | 2024 | |
| Tandem Diabetes Care, INC. | $41.08 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Companion Medical, INC. | $31.00 | 2019 | |
| Horizon Therapeutics Plc | $24.45 | 2023 | Tepezza |
| Embecta Corp. | $23.36 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Senseonics, Incorporated | $22.00 | 2019 | |
| Averitas Pharma INC. | $20.81 | 2024 | Qutenza |
| Regeneron Healthcare Solutions, INC. | $18.20 | 2024 | Dupixent |
| Currax Pharmaceuticals LLC | $16.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Goldberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.